Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male.

Abstract

Pfizer-BioNTech COVID-19 (BNT162b2) conferred a high level of protection against Covid-19 with a proven short-term safety profile. Although cases of vaccine-associated myopericarditis have been reported, the existence of rhabdomyolysis without myocarditis has not yet been published. A 16-year-old, healthy male patient, who did not use any herbal or illegal drugs before, was admitted with muscle pain that developed after the second dose of BNT162b2 vaccine. Cardiac examination and heart enzymes were normal and the patient had significantly higher creatinine kinase levels. The patient, whose enzymes returned to normal with only force hydration therapy, recovered without complications. Reporting the side effects of the vaccine, which has a short history of application to large populations, is of vital importance in the conduct of vaccine development studies and in identifying the risky group in terms of side effects.

• Authors: Murat Sutcu, Doruk Gul, Fatih Atik, Manolya Kara
• Journal: Malawi medical journal : the journal of Medical Association of Malawi (Malawi Med J) Vol. 34 Issue 2 Pg. 154-156 (06 2022) ISSN: 1995-7270 [Electronic] Malawi
• PMID: 35991822 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2022 The College of Medicine and the Medical Association of Malawi.

Chemical References

• COVID-19 Vaccines
• BNT162 Vaccine

Topics

• Adolescent
• BNT162 Vaccine (administration & dosage, adverse effects)
• COVID-19 (prevention & control)
• COVID-19 Vaccines (administration & dosage, adverse effects)
• Humans
• Male
• Myocarditis (chemically induced, etiology)
• Rhabdomyolysis (chemically induced, diagnosis, etiology, therapy)
• Treatment Outcome